- Home
- Products
- Customized ADCs
- FZD1
- Anti-FZD1 (Vantictumab)-MC-MMAF ADC
Anti-FZD1 (Vantictumab)-MC-MMAF ADC (CAT#: ADC-W-1180)
This ADC product is comprised of an anti-FZD1 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FZD1
- Alternative Names
- FZD1; frizzled family receptor 1; frizzled (Drosophila) homolog 1 , frizzled 1, seven transmembrane spanning receptor , frizzled homolog 1 (Drosophila); frizzled-1; DKFZp564G072; frizzled; Drosophila; homolog of; 1; Wnt receptor; fz-1; fzE1; hFz1; frizzled homolog 1; frizzled, Drosophila, homolog of, 1; frizzled 1, seven transmembrane spanning receptor; FLJ95923;
- Target Entrez Gene ID
- 8321
- Target UniProt ID
- Q9UP38
- Overview
- Members of the 'frizzled' gene family encode 7-transmembrane domain proteins that are receptors for Wnt signaling proteins. The FZD1 protein contains a signal peptide, a cysteine-rich domain in the N-terminal extracellular region, 7 transmembrane domains, and a C-terminal PDZ domain-binding motif. The FZD1 transcript is expressed in various tissues.
- Overview
- Human Anti-FZD1 IgG2-lambda antibody, Vantictumab
- Generic name
- Vantictumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-HIV-1 (Suvizumab)-MC-MMAF ADC (CAT#: ADC-W-2110)
- Anti-CXCL10 (Eldelumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1013)
- Anti-CD33-Mc-MMAF ADC-3 (CAT#: ADC-W-114)
- Anti-RSV (Felvizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2003)
- Anti-TNFRSF10A (Mapatumumab)-SPDB-DM4 ADC (CAT#: ADC-W-2415)
- Anti-Fibrin II-beta chain (Biciromab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1998)
- Anti-Rabies Virus Glycoprotein (Foravirumab)-MC-MMAF ADC (CAT#: ADC-W-1966)
- Anti-FZD1 (Vantictumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1181)
- Anti-ERBB2 (trastuzumab)-AcLys-VC-PABC-MMAD ADC (CAT#: ADC-W-631)
- Anti-CD44 (Bivatuzumab)-MC-MMAF ADC (CAT#: ADC-W-2544)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1180. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1182 | Anti-FZD1 (Vantictumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1181 | Anti-FZD1 (Vantictumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1178 | Anti-FZD1 (Vantictumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1183 | Anti-FZD1 (Vantictumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1179 | Anti-FZD1 (Vantictumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-485 | Anti-EphA2-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-493 | Anti-CD19-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-115 | Anti-CD33-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2573 | Anti-SLC34A2 (Lifastuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.